Effect of Baseline Glycosylated Hemoglobin A1c on Glycemic Control and Diabetes Management Following Initiation of Once-Daily Insulin Detemir in Real-Life Clinical Practice

2013 ◽  
Vol 19 (3) ◽  
pp. 462-470 ◽  
Author(s):  
Salvatore Caputo ◽  
Henning Andersen ◽  
Marcel Kaiser ◽  
Eddy Karnieli ◽  
Luigi Meneghini ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Glycemic Control ◽  
Insulin Detemir ◽  
Hemoglobin A1c ◽  
Diabetes Management ◽  
Glycosylated Hemoglobin ◽  
Real Life ◽  
Once Daily ◽  
Daily Insulin ◽  
Glycosylated Hemoglobin A1c

scholarly journals The Eradication of Helicobacter pylori does not Affect Glycemic Control in Japanese Subjects with Type 2 Diabetes

2013 ◽  
Vol 4 ◽  
pp. JCM.S10828 ◽  
Author(s):  
Yoshiharu Wada ◽  
Yoshiyuki Hamamoto ◽  
Yukiko Kawasaki ◽  
Sachiko Honjo ◽  
Kanta Fujimoto ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Helicobacter Pylori ◽  
Glycemic Control ◽  
Hemoglobin A1c ◽  
Glycosylated Hemoglobin ◽  
Eradication Therapy ◽  
Glycosylated Hemoglobin A1c ◽  
H Pylori ◽  
Japanese Subjects

Since infection with Helicobacter pylori has been suggested to play a pathogenic role in diabetes mellitus, we investigated whether eradication therapy for H. pylori might affect glycemic control in Japanese subjects with type 2 diabetes. A total of 72 subjects (55 males, 17 females; aged 63.7 years) with type 2 diabetes who received eradication therapy for H. pylori were included. The change of their blood glycosylated hemoglobin (A1C) levels 3 months before (-3 m) the H. pylori eradication, as well as 3 months (3 m) and 6 months (6 m) after were evaluated. Their A1C levels did not show any significant change after therapy {6.9 [0.1]% (-3 m) to 7.0 [0.1]% (3 m); P = 0.3, 7.0 [0.1] (6 m); P = 0.3}. Our findings suggest that the eradication therapy for H. pylori does not, at least profoundly, affect glycemic control in Japanese subjects with type 2 diabetes.

scholarly journals Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Alessandro Scorsone ◽  
Gabriella Saura ◽  
Mattia Fleres ◽  
Lucia Spano ◽  
Vito Aiello ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Life Experience ◽  
Glycosylated Hemoglobin ◽  
Real Life ◽  
Once Daily ◽  
Glucose Lowering ◽  
Lipid Parameters ◽  
Inadequate Glycemic Control

Introduction. This study aimed at evaluating the efficacy and safety of dapagliflozin in patients with type 2 diabetes (T2D) who also received metformin in clinical practice in Italy. Methods. This was a retrospective observational study and it included data from patients who received dapagliflozin 10 mg once daily in conjunction with metformin for 12 months (DAPA + MET). In those with inadequate glycemic control, insulin or glimepiride was added after 30 days (DAPA + MET + other glucose-lowering drugs). Efficacy assessments included glycosylated hemoglobin (HbA1c) levels at 6 and 12 months, as well as body mass index (BMI) and lipid parameters at 12 months. Safety was also assessed. Results. Data on 66 patients were included. In both groups, HbA1c was significantly reduced at 6 and 12 months compared with baseline and significant reductions in HbA1c were observed at 12 months compared with 6 months. Over the 12-month treatment period, dapagliflozin significantly reduced BMI in both groups. No significant changes in lipid parameters were observed in either group and no detrimental effects on renal function were detected. Conclusions. Dapagliflozin is effective and safe in patients with T2D also receiving metformin. Glycemic control was already achieved with dapagliflozin + metformin, and add-on therapy was not associated with further improvements.

scholarly journals Diabetes and Frail Older Patients: Glycemic Control and Prescription Profile in Real Life

Pharmacy ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 115
Author(s):  
Anne-Sophie Mangé ◽  
Arnaud Pagès ◽  
Sandrine Sourdet ◽  
Philippe Cestac ◽  
Cécile McCambridge
Keyword(s):  
Glycemic Control ◽  
Older Patients ◽  
Diabetes Management ◽  
Real Life ◽  
Cross Sectional ◽  
Glucose Lowering ◽  
Frailty Status ◽  
Frail Patients ◽  
Patients With Diabetes ◽  
Hba1c Target

(1) Background: The latest recommendations for diabetes management adapt the objectives of glycemic control to the frailty profile in older patients. The purpose of this study was to evaluate the proportion of older patients with diabetes whose treatment deviates from the recommendations. (2) Methods: This cross-sectional observational study was conducted in older adults with known diabetes who underwent an outpatient frailty assessment in 2016. Glycated hemoglobin (HbA1c) target is between 6% and 7% for nonfrail patients and between 7% and 8% for frail patients. Frailty was evaluated using the Fried criteria. Prescriptions of glucose-lowering drugs were analyzed based on explicit and implicit criteria. (3) Results: Of 110 people with diabetes with an average age of 81.7 years, 67.3% were frail. They had a mean HbA1c of 7.11%. Of these patients, 60.9% had at least one drug therapy problem in their diabetes management and 40.9% were potentially overtreated. The HbA1c distribution in relation to the targets varied depending on frailty status (p < 0.002), with overly strict control in frail patients (p < 0.001). (4) Conclusions: Glycemic control does not seem to be routinely adjusted to the health of frail patients. Several factors can lead to overtreatment of these patients.

scholarly journals Diabetes Mellitus And Glycosylated Hemoglobin A1c

2018 ◽  
Vol 1 (2) ◽  
pp. 112-117
Author(s):  
Shiva Raj KC
Keyword(s):  
Diabetes Mellitus ◽  
Hemoglobin A1c ◽  
Glycosylated Hemoglobin ◽  
Time Frame ◽  
World Health ◽  
Chronic Hyperglycemia ◽  
Glycosylated Hemoglobin A1c ◽  
Health Organization ◽  
Global Health Problem

Diabetes mellitus is a global health problem in 21st century. The incidence of diabetes mellitus is in rise and is estimated to be more prevalent in coming years. It is becoming one of the most common non-infectious and non-neoplastic causes of morbidity and mortality. Various complications are associated with diabetes mellitus. With control of blood glucose level, complications of diabetes mellitus can be minimized. In different time frame, different parameters and level have been used to diagnose diabetes. Glycosylated hemoglobin A1c is one of the reliable indicator of chronic hyperglycemia. In 2011, World Health Organization has included HbA1c in the diagnostic criteria. Various methods are used to detect the level of HbA1c.  Glycosylated hemoglobin is being used in the management of diabetes mellitus. Various studies have shown its prognostic implication in micro and macrovascular complications. Here we discuss various methods of estimation of HbA1c, various role of HbA1c in the management of Diabetes Mellitus and limitation of the test.  

Sign in / Sign up

Export Citation Format

Share Document